Report Description

Global gynecology drugs market stood at USD14139.56 million in 2021 and is forecast to grow at CAGR of 8.64% in the forecast years, 2023-2027 on account of rapidly increasing instances of gynecology cancer and other gynecology disorders. Gynecology drugs are therapeutics and biologics that are administered for the treatment of gynecology disorders and ailments to the women patient. Gynecology disorders affect the reproductive system of the females and cause infection or functional failure in the reproductive organs like the uterus, urinary bladder, urethra, ovaries, appendages, etc.

The Increasing Number of Gynecological Disorders

The rising global frequency of various gynecological diseases and disorders has greatly boosted the demand for gynecological medications. The majority of the world's population is inclined to use gynecological pharmaceuticals, resulting in potential demand opportunities for the gynecology drug industry. Cervical cancer, for example, is the fourth most prevalent malignancy among women, according to the World Health Organization. Cervical cancer was diagnosed in around 570 000 women worldwide in 2018, with approximately 311 000 women dying from the disease.

Increasing Elderly Female Population

During the projected period, the worldwide gynecological pharmaceuticals market is expected to benefit from an increase in the percentage of older females. As the population of elderly women grows, it is expected that they would face more gynecological issues. According to the World Population Prospects, as of 2021, there were approximately 9.5 percent females over the age of 60, with the majority of the female population susceptible to gynecological infections or disorders. As a result, the growing proportion of elderly women is boosting the global market for gynecological medications.


Click here to download the sample

Market Segmentation

The global gynecology drugs market is segmented by therapeutics, indication, distribution channel, regional distribution, and competitive landscape. Based on therapeutics, the market is further bifurcated between hormonal therapy and non-hormonal therapy. Non-hormonal therapy is anticipated to hold the largest share of the market due to its advantages of efficient treatments. Moreover, rapid advancements in new drug development supports the segment's growth in the next five years. Hormonal therapy is also expected to hold a significant share of the market owing to the rising demand for new technologically advanced medicine, although the therapy has certain side effects such as the risk of breast cancer.

Major companies in the market are Amgen Inc., F. Hoffmann La Roche Ltd., Novartis AG, Bayer AG, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, AstraZeneca Plc, Lupin Limited, Johnson and Johnson, Sanofi SA, Ferring Pharmaceuticals among others. The market players are actively involved in the technological advancements of the therapeutics as well as research and development of the medical devices involved in the administration of the gynecology drugs. Other strategies include partnerships among the market players.

Attribute

Details

Market size value in 2021

USD 14139.56 Million

Revenue Forecast in 2027

USD 21395.67 Million

United States Market Size Value in 2021

USD 3624.92 Million

Base Year

2021

Historical Years

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022E-2027F

Report Coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered

·         Therapeutics

·         Indication

·         Distribution Channel

Regional Scope

North America; Asia Pacific; Europe, South America; Middle East & Africa

Country Scope

United States; Canada; Mexico; Germany; France; United Kingdom; Italy; Spain; China; Japan; India; Australia; South Korea; South Africa; Saudi Arabia; UAE; Brazil; Argentina; Colombia

Key Companies Profiled

Amgen Inc., F. Hoffmann La Roche Ltd., Novartis AG, Bayer AG, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, AstraZeneca Plc, Lupin Limited, Johnson and Johnson, Sanofi SA, Ferring Pharmaceuticals

Customization Scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/pdf format on special request)

 

Report Scope:

In this report, global gynecology drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Gynecology Drugs Market, By Therapeutics:
    • Non-Hormonal Therapy
    • Hormonal Therapy
  • Global Gynecology Drugs Market, By Indication:
    • Contraception
    • Gynecology Infections
    • Female Infertility
    • Postmenopausal disorders
    • Polycystic Ovary Syndrome
    • Gynecology Cancers
    • Endometriosis
  • Global Gynecology Drugs Market, By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
  • Global Gynecology Drugs Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global gynecology drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of content

1.    Product Overview

2.    Research Methodology

3.    Executive Summary

4.    Voice of Customer

4.1.  Brand Awareness

4.2.  Factors Affecting Purchase Decision

4.3.  Product Preference, By Therapeutics

5.    Impact of COVID-19 on Global Gynecology Drugs Market

6.    Global Gynecology Drugs Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Therapeutics (Non-Hormonal Therapy vs Hormonal Therapy)

6.2.2.     By Indication (Contraception, Gynecology infections, Female infertility, Postmenopausal Disorders, Polycystic Ovary Syndrome, Gynecology Cancer, Endometriosis)

6.2.3.     By Distribution Channel (Retail Pharmacies, Hospital Pharmacies Online Pharmacies)

6.2.4.     By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

6.2.5.     By Company (2021)

6.3.  Product Market Map

7.    North America Gynecology Drugs Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Therapeutics

7.2.2.     By Indication

7.2.3.     By Distribution Channel

7.2.4.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Gynecology Drugs Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Therapeutics

7.3.1.2.2.             By Indication

7.3.1.2.3.             By Distribution Channel

7.3.2.     Canada Gynecology Drugs Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Therapeutics

7.3.2.2.2.             By Indication

7.3.2.2.3.             By Distribution Channel

7.3.3.     Mexico Gynecology Drugs Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Therapeutics

7.3.3.2.2.             By Indication

7.3.3.2.3.             By Distribution Channel

8.    Europe Gynecology Drugs Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Therapeutics

8.2.2.     By Indication

8.2.3.     By Distribution Channel

8.2.4.     By Country

8.3.  Europe: Country Analysis

8.3.1.     Germany Gynecology Drugs Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Therapeutics

8.3.1.2.2.             By Indication

8.3.1.2.3.             By Distribution Channel

8.3.2.     France Gynecology Drugs Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Therapeutics

8.3.2.2.2.             By Indication

8.3.2.2.3.             By Distribution Channel

8.3.3.     United Kingdom Gynecology Drugs Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Therapeutics

8.3.3.2.2.             By Indication

8.3.3.2.3.             By Distribution Channel

8.3.4.     Italy Gynecology Drugs Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Therapeutics

8.3.4.2.2.             By Indication

8.3.4.2.3.             By Distribution Channel

8.3.5.     Spain Gynecology Drugs Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Therapeutics

8.3.5.2.2.             By Indication

8.3.5.2.3.             By Distribution Channel

9.    Asia Pacific Gynecology Drugs Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Therapeutics

9.2.2.     By Indication

9.2.3.     By Distribution Channel

9.2.4.     By Country

9.3.  Asia Pacific: Country Analysis

9.3.1.     China Gynecology Drugs Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Therapeutics

9.3.1.2.2.             By Indication

9.3.1.2.3.             By Distribution Channel

9.3.2.     Japan Gynecology Drugs Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Therapeutics

9.3.2.2.2.             By Indication

9.3.2.2.3.             By Distribution Channel

9.3.3.     India Gynecology Drugs Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Therapeutics

9.3.3.2.2.             By Indication

9.3.3.2.3.             By Distribution Channel

9.3.4.     Australia Gynecology Drugs Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Therapeutics

9.3.4.2.2.             By Indication

9.3.4.2.3.             By Distribution Channel

9.3.5.     South Korea Gynecology Drugs Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Therapeutics

9.3.5.2.2.             By Indication

9.3.5.2.3.             By Distribution Channel

10.  South America Gynecology Drugs Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Therapeutics

10.2.2.  By Indication

10.2.3.  By Distribution Channel

10.2.4.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Gynecology Drugs Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Therapeutics

10.3.1.2.2.           By Indication

10.3.1.2.3.           By Distribution Channel

10.3.2.  Argentina Gynecology Drugs Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Therapeutics

10.3.2.2.2.           By Indication

10.3.2.2.3.           By Distribution Channel

10.3.3.  Colombia Gynecology Drugs Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Therapeutics

10.3.3.2.2.           By Indication

10.3.3.2.3.           By Distribution Channel

11.  Middle East and Africa Gynecology Drugs Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Therapeutics

11.2.2.  By Indication

11.2.3.  By Distribution Channel

11.2.4.  By Country

11.3.              Middle East and Africa: Country Analysis

11.3.1.  South Africa Gynecology Drugs Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Therapeutics

11.3.1.2.2.           By Indication

11.3.1.2.3.           By Distribution Channel

11.3.2.  Saudi Arabia Gynecology Drugs Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Therapeutics

11.3.2.2.2.           By Indication

11.3.2.2.3.           By Distribution Channel

11.3.3.  UAE Gynecology Drugs Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Therapeutics

11.3.3.2.2.           By Indication

11.3.3.2.3.           By Distribution Channel

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends and Developments

14.  Competitive Landscape

14.1.              Company profiles

14.1.1.  Eli Lilly and Company Ltd.

14.1.2.  Pfizer Inc.

14.1.3.  Merck & Co., Inc.

14.1.4.  Amgen Inc.

14.1.5.  AstraZeneca Plc

14.1.6.  F. Hoffmann-La Roche Ltd.

14.1.7.  Allergan Plc.

14.1.8.  Bayer AG

14.1.9.  Abbott Laboratories Ltd.

14.1.10.   AbbVie Inc.

14.1.11.   GlaxoSmithKline Plc

14.1.12.   Novartis Ltd.

14.1.13.   Lupin Pharmaceuticals, Inc.

14.1.14.   Johnson and Johnson Inc.

14.1.15.   Sanofi SA

15.  Strategic Recommendations

16.  About Us & Disclaimer

Figures and Tables

Figure 1:          Global Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 2:          Global Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 3:          Global Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 4:          Global Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 5:          Global Gynecology Drugs Market Share, By Region, By Value, 2017-2027F

Figure 6:          Global Gynecology Drugs Market Share, By Company, By Value, 2021

Figure 7:          Global Gynecology Drugs Market Map, By Therapeutics, Market Size (USD Million) & Growth Rate (%), 2021

Figure 8:          Global Gynecology Drugs Market Map, By Indication, Market Size (USD Million) & Growth Rate (%), 2021

Figure 9:          Global Gynecology Drugs Market Map, By Distribution Channel, Market Size (USD Million) & Growth Rate (%), 2021

Figure 10:        Global Gynecology Drugs Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021

Figure 11:        North America Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 12:        North America Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 13:        North America Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 14:        North America Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 15:        North America Gynecology Drugs Market Share, By Country, By Value, 2017-2027F

Figure 16:        United States Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 17:        United States Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 18:        United States Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 19:        United States Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 20:        Canada Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 21:        Fertility Rate in Canada, 2005, 2010, 2015, 2020

Figure 22:        Canada Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 23:        Canada Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 24:        Canada Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 25:        Mexico Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 26:        Mexico Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 27:        Mexico Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 28:        Mexico Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 29:        Europe Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 30:        Europe Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 31:        Europe Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 32:        Europe Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 33:        Europe Gynecology Drugs Market Share, By Country, By Value, 2017-2027F

Figure 34:        Germany Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 35:        Fertility Rate in Germany, 2005, 2010, 2015, 2020

Figure 36:        Germany Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 37:        Germany Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 38:        Germany Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 39:        France Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 40:        France Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 41:        France Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 42:        France Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 43:        United Kingdom Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 44:        Prevalence of Menopause Symptoms Experienced by Women at Work in United Kingdom, 2021

Figure 45:        United Kingdom Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 46:        United Kingdom Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 47:        United Kingdom Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 48:        Italy Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 49:        Fertility Rate in Italy, 2005, 2010, 2015, 2020

Figure 50:        Italy Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 51:        Italy Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 52:        Italy Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 53:        Spain Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 54:        Spain Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 55:        Spain Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 56:        Spain Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 57:        Asia Pacific Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 58:        Asia Pacific Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 59:        Asia Pacific Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 60:        Asia Pacific Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 61:        Asia Pacific Gynecology Drugs Market Share, By Country, By Value, 2017-2027F

Figure 62:        China Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 63:        China Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 64:        China Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 65:        China Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 66:        Japan Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 67:        Estimated Share of Women in Japan Using any Contraceptive Method, 2005, 2010, 2015, 2020

Figure 68:        Japan Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 69:        Japan Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 70:        Japan Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 71:        India Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 72:        Polycystic Ovary Syndrome Issues Among Women Across India, By Age Group, 2020

Figure 73:        India Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 74:        India Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 75:        India Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 76:        Australia Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 77:        Australia Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 78:        Australia Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 79:        Australia Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 80:        South Korea Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 81:        South Korea Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 82:        South Korea Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 83:        South Korea Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 84:        South America Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 85:        South America Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 86:        South America Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 87:        South America Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 88:        South America Gynecology Drugs Market Share, By Country, By Value, 2017-2027F

Figure 89:        Brazil Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 90:        Fertility Rate in Brazil, 2005, 2010, 2015, 2020

Figure 91:        Brazil Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 92:        Brazil Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 93:        Brazil Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 94:        Argentina Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 95:        Total Female Population of Argentina, by Age Group, 2020 (in Millions)

Figure 96:        Argentina Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 97:        Argentina Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 98:        Argentina Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 99:        Colombia Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 100:      Colombia Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 101:      Colombia Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 102:      Colombia Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 103:      Middle East & Africa Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 104:      Middle East & Africa Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 105:      Middle East & Africa Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 106:      Middle East & Africa Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 107:      Middle East & Africa Gynecology Drugs Market Share, By Country, By Value, 2017-2027F

Figure 108:      South Africa Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 109:      Fertility Rate in South Africa, 2005, 2010, 2015, 2020

Figure 110:      South Africa Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 111:      South Africa Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 112:      South Africa Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 113:      Saudi Arabia Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 114:      Saudi Arabia Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 115:      Saudi Arabia Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 116:      Saudi Arabia Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

Figure 117:      UAE Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F

Figure 118:      Total Female Population of UAE, by Age Group, 2020 (in Millions)

Figure 119:      UAE Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F

Figure 120:      UAE Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F

Figure 121:      UAE Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

List of Tables:

Table 1:           Infertility Statistics of United States

Table 2:           Ovary Cancer Cases in Mexico, 2020

Table 3:           Ovary Cancer Cases in France, 2020

Table 4:           Ovary Cancer Cases in Spain, 2020

Table 5:           Ovary Cancer Cases in China, 2020

Table 6:           Cancer Statistics of Australia, 2020

Table 7:           Ovary Cancer Cases in South Korea, 2020

Table 8:           Ovary Cancer Cases in Colombia, 2020

Table 9:           Cervix Uteri Cancer Cases in Saudi Arabia, 2020


Frequently asked questions

down-arrow

Rapidly increasing instances of gynecology cancer, and other gynecology disorders and increased fatality rate of the women population due to these diseases are driving the growth of the global gynecology drugs market in the forecast years, 2023-2027. The market of the Asia Pacific is valued to reach USD 5462.31 Million.

down-arrow

United States dominated the market in 2021 with a market value of USD3624.92 million. This can be ascribed to the widespread use of gynecological drugs for treating different problems.

down-arrow

Amgen Inc., F. Hoffmann La Roche Ltd., Novartis AG, Bayer AG, Merck & Co., Inc., are the dominating companies in the global gynecology drugs market.

down-arrow

Lack of awareness in rural areas, high cost and alternative treatment methods are few challenges faced by the global gynecology drugs market.

profile

Sakshi Bajaal

Business Consultant
Press Release

Gynecology Drugs Market to reach USD 21395.67 Million by 2027

Jun, 2022

Growing awareness about women health is driving the growth of Global Gynecology Drugs Market in the forecast period 2023-2027.